Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 20/20 | 0.84 |
| ▸ | OPRM1 | P35372 | 17/20 | 0.84 |
| ▸ | OPRK1 | P41145 | 17/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6334592 | 0.92 | OPRD1 (0.86) | OPRD1OPRM1OPRK1 | |
| SCHEMBL6327345 | 0.92 | OPRD1 (0.86) | OPRD1OPRM1OPRK1 | |
| SCHEMBL6325512 | 0.91 | OPRD1 (0.84) | OPRD1OPRM1OPRK1 | |
| SCHEMBL6326841 | 0.91 | OPRD1 (0.84) | OPRD1OPRM1OPRK1 | |
| SCHEMBL6326767 | 0.90 | OPRD1 (0.83) | OPRD1OPRM1OPRK1 | |
| SCHEMBL6329511 | 0.89 | OPRD1 (0.84) | OPRD1OPRM1OPRK1 | |
| SCHEMBL6325254 | 0.86 | OPRD1 (0.84) | OPRD1OPRM1OPRK1 | |
| SCHEMBL6326358 | 0.86 | OPRD1 (0.84) | OPRD1OPRM1OPRK1 | |
| SCHEMBL6329792 | 0.86 | OPRD1 (0.84) | OPRD1OPRM1OPRK1 | |
| SCHEMBL6173648 | 0.85 | OPRM1 (0.84) | OPRD1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6875777-B2 | Compounds | ASTRAZENECA AB (SE) | 2005-04-05 | — | — | US | claimed |
| EP-1242406-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-03-17 | — | — | EP | claimed |
| US-20030036552-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2003-02-20 | — | — | US | claimed |
| EP-1242406-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2002-09-25 | — | — | EP | claimed |
| WO-2001046263-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | claimed |
| US-6875777-B2 | Compounds | ASTRAZENECA AB (SE) | 2005-04-05 | — | — | US | disclosed |
| EP-1242406-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-03-17 | — | — | EP | disclosed |
| US-20030036552-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2003-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030036552-A1 | Novel compounds | ARRB1, OPRK1, OPRM1 | OPRD1 4/4885OPRM1 3/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.